{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:56:06Z","timestamp":1782536166442,"version":"3.54.5"},"reference-count":34,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.3892\/ol.2015.3156","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T12:23:05Z","timestamp":1430137385000},"page":"439-442","source":"Crossref","is-referenced-by-count":15,"title":["Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws"],"prefix":"10.3892","volume":"10","author":[{"given":"MERAL","family":"G\u00dcNALDI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CIGDEM USUL","family":"AFSAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERNA BOZKURT","family":"DUMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ISMAIL OGUZ","family":"KARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UFUK","family":"TATLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERKSOY","family":"SAH\u0130N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,4,27]]},"reference":[{"key":"key20180108101238_b1-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"key20180108101238_b2-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology Bisphosphonates Expert Panel: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108101238_b3-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: Mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"issue":"Suppl 2","key":"key20180108101238_b4-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: Pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"key20180108101238_b5-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jbmr.5650030210","article-title":"Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate","volume":"3","author":"L\u00f6wik","year":"1988","journal-title":"J Bone Miner Res"},{"key":"key20180108101238_b6-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF00316291","article-title":"The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number","volume":"54","author":"Piper","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"key20180108101238_b7-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"key20180108101238_b8-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"34967","DOI":"10.1074\/jbc.274.49.34967","article-title":"Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase","volume":"274","author":"Reszka","year":"1999","journal-title":"J Biol Chem"},{"key":"key20180108101238_b9-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO;2-W","article-title":"Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies","volume":"88","author":"Diel","year":"2000","journal-title":"Cancer"},{"key":"key20180108101238_b10-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s002239900535","article-title":"The effect of alendronate on cytokine production, adhesion molecule expression and transendothelial migration of human peripheral blood mononuclear cells","volume":"63","author":"Pietschmann","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"key20180108101238_b11-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.cad.0000198909.52701.0f","article-title":"A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice","volume":"17","author":"Ledoux","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"Suppl","key":"key20180108101238_b12-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"key20180108101238_b13-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"issue":"Suppl 1","key":"key20180108101238_b14-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2010.06.003","article-title":"The molecular basis of bisphosphonate activity: a preclinical perspective","volume":"37","author":"Green","year":"2010","journal-title":"Semin Oncol"},{"key":"key20180108101238_b15-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"key20180108101238_b16-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"111","DOI":"10.14712\/18059694.2015.47","article-title":"Bisphosphonate-related osteonecrosis of the jaws A severe side effect of bisphosphonate therapy","volume":"55","author":"Janovsk\u00e1","year":"2012","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"key20180108101238_b17-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bjoms.2011.08.004","article-title":"Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases","volume":"50","author":"Ferlito","year":"2012","journal-title":"Br J Oral Maxillofac Surg"},{"key":"key20180108101238_b18-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.surge.2011.09.002","article-title":"Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review","volume":"10","author":"McLeod","year":"2012","journal-title":"Surgeon"},{"key":"key20180108101238_b19-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.10.009","article-title":"Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis","volume":"71","author":"Tubiana-Hulin","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180108101238_b20-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw \u2212 2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J"},{"key":"key20180108101238_b21-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key20180108101238_b22-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108101238_b23-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"key20180108101238_b24-ol-0-0-3156","first-page":"504","article-title":"Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: A retrospective study","volume":"19","author":"Brufsky","year":"2013","journal-title":"Breast J"},{"key":"key20180108101238_b25-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108101238_b26-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcms.2009.06.005","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk","volume":"38","author":"Kos","year":"2010","journal-title":"J Craniomaxillofac Surg"},{"key":"key20180108101238_b27-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.oraloncology.2010.11.007","article-title":"Surgery-triggered and non-surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicentre study","volume":"47","author":"Vescovi","year":"2011","journal-title":"Oral Oncol"},{"key":"key20180108101238_b28-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"E1807","DOI":"10.1210\/jc.2013-2434","article-title":"Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single centre study","volume":"98","author":"Molcho","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"key20180108101238_b29-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"key20180108101238_b30-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"key20180108101238_b31-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"key20180108101238_b32-ol-0-0-3156","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: Results of an Italian multicenter study and review of the literature","author":"Fusco","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"key20180108101238_b33-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.eururo.2014.02.040","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"key20180108101238_b34-ol-0-0-3156","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1200\/jco.2008.26.15_suppl.9588","article-title":"Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and\/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)","volume":"26","author":"McArthur","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.3156\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:51:58Z","timestamp":1515415918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.3156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,4,27]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3892\/ol.2015.3156"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.3156","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,27]]}}}